The report "Vaccine Adjuvants Market by Product (Emulsions, Pathogen, Saponin, Particulate), ROA (Subcutaneous, Intramuscular), Disease Type (Infectious, Cancer), Vaccine (Human, Veterinary (Companion, Livestock)), Type (Organic, Inorganic) - Global Forecast to 2029", is estimated to expand to a value of USD 0.96 billion by 2029 from USD 0.70 billion in 2024, growing at a CAGR of 6.5%. Some of the prominent factors driving the growth of the market are increased cases of infectious and non-communicable diseases, large-scale vaccination campaigns by governments and organizations such as WHO and GAVI, and advancements in adjuvant technology. Additionally, rising demand for livestock and aquaculture health, combined with zoonotic disease prevention and increased public & private funding for the development of vaccines, is likely to fuel the market growth in coming years.

Browse 490 market data Tables and 50 Figures spread through 388 Pages and in-depth TOC on "Vaccine Adjuvants Market by Product (Emulsions, Pathogen, Saponin, Particulate), ROA (Subcutaneous, Intramuscular), Disease Type (Infectious, Cancer), Vaccine (Human, Veterinary (Companion, Livestock)), Type (Organic, Inorganic) - Global Forecast to 2029"

Download PDF- https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=152603894

The emulsion-based adjuvants segment accounted for the dominant share in 2023.

The market is segmented by products into emulsion-based adjuvants, pathogen components, saponin-based adjuvants, particulate-based adjuvants, and other products. The emulsion-based adjuvants segment dominated the market in 2023 and is anticipated to retain its dominance throughout the forecast period. The pathogen components segment is likely to grow at a significant CAGR owing to the increased use of pathogen components adjuvants in livestock and aquaculture vaccines and increased research and development.

The infectious disease segment is likely to grow at a significant CAGR from 2024 to 2029.

The market is segmented by disease type into infectious diseases, cancer, and other diseases. The infectious diseases segment dominated the market in 2023. The high prevalence and global impact of diseases like influenza, COVID-19, malaria, and hepatitis and the growing focus on immunization programs are some of the factors driving the segment's growth. The cancer segment is anticipated to grow at a significant CAGR owing to increasing research and development in cancer immunotherapy and significant investment and research for cancer vaccines.

North America region dominated the vaccine adjuvants market.

The vaccine adjuvants market is segmented by region into North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa. North America dominated the market due to its robust healthcare infrastructure, high R&D investment, and strong focus on immunization programs. Furthermore, the region's dominance is further fueled by government-supported vaccine initiatives, high disease awareness, and strategic investments in pandemic preparedness.

Prominent players operating in the vaccine adjuvants market GSK Plc (UK), SEPPIC (France), Croda International Plc (UK), SPI Pharma (UK), Agenus Inc. (US), Phibro Animal Health Corporation (US), Aurorium (US), Dynavax Technologies Corporation (US) and Novavax (US), among others.

About MarketsandMarkets™

MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.

Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.

MarketsandMarkets’s flagship competitive intelligence and market research platform, "Knowledgestore" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.